Compare CSX Corporation (CSX) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Incyte Corporation — how do they compare? CSX Corporation trades at $47.6 (market cap $87.70B), while Incyte Corporation trades at $112.8 (market cap $22.85B). The key difference: CSX Corporation is far larger — about 3.8× Incyte Corporation's market cap, and CSX Corporation pays a 1.18% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Incyte Corporation for 33 Days on average.
| CSX | INCY | |
|---|---|---|
Market Cap | $87.70B | $22.85B |
Volume | 6,980,781 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $53.21 | $129.93 |
52-Week Low | $33.68 | $83.80 |
Typical Hold Time | 55 Days | 33 Days |
Enterprise Value | $105.66B | $18.35B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $46.81, down 1.45% with a bearish technical signal. The railroad operator shows mixed fundamentals with declining revenue from $14.9B in 2022 to $14.1B in 2025, though net income margins remain strong at 22.21%. Recent earnings show two beats and one miss, with Q3 2026 results pending. Analyst consensus is bullish with 59% buy ratings and a $51 price target, representing 9% upside from current levels.
CSX offers steady dividend income and pricing power in an irreplaceable freight network, but faces revenue pressure and elevated valuation multiples. The stock's investment case hinges on operational efficiency gains and freight volume recovery, balanced against economic sensitivity and competitive pressures in the transportation sector.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
